for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Clearside Biomedical Inc

CLSD.O

Latest Trade

2.19USD

Change

-0.04(-1.79%)

Volume

266,247

Today's Range

2.15

 - 

2.27

52 Week Range

2.15

 - 

7.73

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.23
Open
2.19
Volume
266,247
3M AVG Volume
10.21
Today's High
2.27
Today's Low
2.15
52 Week High
7.73
52 Week Low
2.15
Shares Out (MIL)
59.67
Market Cap (MIL)
133.06
Forward P/E
-13.79
Dividend (Yield %)
--

Next Event

Q4 2021 Clearside Biomedical Inc Earnings Release

Latest Developments

More

Clearside Biomedical Inc Announces Positive Safety Results From Oasis Phase 1/2A Clinical Trial Of Cls-Ax (Axitinib Injectable Suspension) For The Treatment Of Wet AMD

Bausch + Lomb & Clearside Biomedical Announce FDA Approval Of Xipere For Suprachoroidal Use

Clearside Biomedical Expands Xipere License Agreement With Arctic Vision To Include Australia, New Zealand, India And Asean Countries

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Clearside Biomedical Inc

Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Its proprietary suprachoroidal space (SCS) microinjector targeting SCS offers access to the macula, retina and choroid where sight-threatening disease often occurs. The SCS injection platform is an inherently flexible, in-office, non-surgical procedure intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations. The Company’s suprachoroidal injection platform is a patented approach for delivering pharmacotherapy to the back of the eye through SCS. The Company’s lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection.

Industry

Biotechnology & Drugs

Contact Info

900 N Point Pkwy Ste 200

ALPHARETTA, GA

30005-8995

United States

+1.678.2703631

http://clearsidebio.com/

Executive Leadership

William Douglas Humphries

Independent Chairman of the Board

George Lasezkay

President, Chief Executive Officer, Director

Charles A. Deignan

Chief Financial Officer

Thomas A. Ciulla

Chief Medical Officer, Chief Development Officer

Richard J. Croarkin

Independent Director

Key Stats

2.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.690

2019

-0.810

2020

-0.390

2021(E)

-0.157
Price To Earnings (TTM)
--
Price To Sales (TTM)
34.13
Price To Book (MRQ)
7.45
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-185.59
Return on Equity (TTM)
-113.64

Latest News

Latest News

Bausch, Clearside receive U.S. approval for eye injection

Bausch Health Companies Inc and Clearside Biomedical Inc said on Monday they received approval from the U.S. health regulator for their eye injection, giving patients access to a novel treatment for vision loss resulting from an inflammatory eye condition.

BRIEF-Clearside Biomedical Files For Common Stock Offering Of Upto $50 Mln

* CLEARSIDE BIOMEDICAL INC FILES FOR COMMON STOCK OFFERING OF UPTO $50.0 MILLION - SEC FILING Source text: (https://bit.ly/3cTYqdq) Further company coverage:

BRIEF-Clearside Biomedical Inc Files For Mixed Shelf Of Upto $250 Million - SEC Filing

* CLEARSIDE BIOMEDICAL INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING Source text for Eikon: https://bit.ly/2Wdfghg Further company coverage:

BRIEF-Clearside Biomedical Revises NDA Resubmission Timeline And XIPERE Commercial Deal With Bausch Health

* CLEARSIDE BIOMEDICAL REVISES NDA RESUBMISSION TIMELINE AND XIPERE™ COMMERCIAL PARTNERSHIP WITH BAUSCH HEALTH

BRIEF-Clearside Biomedical Appoints Nancy J. Hutson To Board Of Directors

* CLEARSIDE BIOMEDICAL APPOINTS NANCY J. HUTSON, PH.D. TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Clearside Biomedical Posts Quarterly Loss Per Share Of $0.07

* CLEARSIDE BIOMEDICAL ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Clearside Biomedical Appoints Dr. George Lasezkay As President And Chief Executive Officer

* CLEARSIDE BIOMEDICAL APPOINTS DR. GEORGE LASEZKAY AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

BRIEF-Clearside Biomedical Announces License Agreement With Arctic Vision For Xipere™ In Greater China And South Korea

* CLEARSIDE BIOMEDICAL ANNOUNCES LICENSE AGREEMENT WITH ARCTIC VISION FOR XIPERE™ (TRIAMCINOLONE ACETONIDE SUPRACHOROIDAL INJECTABLE SUSPENSION) IN GREATER CHINA AND SOUTH KOREA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up